medigraphic.com
ISSN 2007-4360 (Impreso)
Asociación Mexicana de Periodontología, Colegio de Periodoncistas A.C

2016, Número 1

<< Anterior

Rev Mex Periodontol 2016; 7 (1)


Agrandamientos gingivales inducidos por medicamentos. Una visión genómica y genética. Revisión de la literatura

Zerón GVJA, Sautto TM

Idioma: Español
Referencias bibliográficas: 45
Paginas: 25-35
Archivo PDF: 345.84 Kb.


RESUMEN

Los medicamentos que están asociados con agrandamientos gingivales se pueden dividir en tres categorías: los anticonvulsivos, los bloqueadores de los canales calcio e inmunosupresores. Actualmente pueden ser reconocidos varios factores de riesgo en la misma cavidad oral que pueden precipitar un agrandamiento gingival como respuesta ante la expresión de genes y la alteración en los mecanismos celulares, donde el biofilm microbiano puede ser un reservorio de moléculas precursoras.


REFERENCIAS (EN ESTE ARTÍCULO)

  2. Rees TD, Levine RA. Systemic drugs as a risk factor for periodontal disease initiation and progression. Compend Contin Educ Dent. 1995; 16: 20-42.

  3. Lewis IK, Hanlon JT, Schmader KE et al. Use of medications with potential oral adverse drug interactions in community dwelling elderly. Spec Care Dentist. 1993; 13: 171-176.

  4. Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowth. Aust Dent J. 1999; 44: 219-232.

  5. Dongari-Bagtzoglou A; Research, Science and Therapy Committee, American Academy of Periodontology. Drug-associated gingival enlargement. J Periodontol. 2004; 75 (10): 1424-1431.

  6. Charles NS, Chavan R, Moon NJ, Nalla S, Mali J, Prajapati A. Drug-induced gingival overgrowth: the genetic dimension. N Am J Med Sci. 2014; 6 (9): 478-480.

  7. Charles N, Ramesh V, Babu KS, Premalatha B. Gene polymorphism in amlodipine-induced gingival hyperplasia: a case report. J Young Pharm. 2012; 4: 287-289.

  8. Johnson RB, Zebrowski EJ, Dai X. Synergistic enhancement of collegenous protein synthesis by human gingival fibroblasts exposed to nifedipine and interleukin-1-beta in vitro. J Oral Pathol Med. 2000; 29: 8-12.

  9. Corręa JD, Queiroz-Junior CM, Costa JE, Teixeira AL, Silva TA. Phenytoin-induced gingival overgrowth: a review of the molecular, immune, and inflammatory features. ISRN Dent. 2011; 2011: 497850.

  10. Iacopino AM, Doxey D, Cutler CW, Nares S, Stoever K, Fojt J et al. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia. J Periodontol. 1997; 68: 73-83.

  11. Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med. 1991; 20 (5): 201-209.

  12. Chung Y, Fu E, Chin YT, Tu HP, Chiu HC, Shen EC et al. Role of Shh and TGF in cyclosporine-enhanced expression of collagen and α-SMA by gingival fibroblast. J Clin Periodontol. 2015; 42 (1): 29-36.

  13. Lijnen P, Petrov V. Transforming growth factor-beta 1-induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. Methods Find Exp Clin Pharmacol. 2002; 24 (6): 333-344.

  14. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. 2007; 170 (6): 1807-1816.

  15. Sobral LM, Kellermann MG, Graner E, Martelli-Junior H, Coletta RD. Cyclosporin A-induced gingival overgrowth is not associated with myofibroblast transdifferentiation. Braz Oral Res. 2010; 24 (2): 182-188.

  16. Mariani G, Calastrini C, Carinci F, Marzola R, Calura G. Ultrastructural features of cyclosporine A-induced gingival hyperplasia. J Periodontol. 1993; 64: 1092-1097.

  17. Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000. 1999; 21: 176-196.

  18. Gürkan A, Becerik S, Öztürk VÖ, Atmaca H, Atilla G, Emingil G. Interleukin-6 family of cytokines in crevicular fluid of renal transplant recipients with and without cyclosporine a-induced gingival overgrowth. J Periodontol. 2014; 86 (9): 1069-1077.

  19. Gürkan A, Emingil G, Afacan B, Berdeli A, Atilla G. Alpha 2 integrin gene (ITGA2) polymorphism in renal transplant recipients with and without drug induced gingival overgrowth. Arch Oral Biol. 2014; 59 (3): 283-288.

  20. Türkoğlu O, Gürkan A, Emingil G, Afacan B, Töz H, Kütükçüler N et al. Are antimicrobial peptides related to cyclosporine A-induced gingival overgrowth? Arch Oral Biol. 2014; 60 (3): 508-515.

  21. Luo Y, Gong Y, Yu Y. Interleukin-10 gene promoter polymorphisms are associated with cyclosporin A-induced gingival overgrowth in renal transplant patients. Arch Oral Biol. 2013; 58 (9): 1199-1207.

  22. Gong Y, Lu J, Ding X. Clinical, microbiologic, and immunologic factors of orthodontic treatment-induced gingival enlargement. Am J Orthod Dentofacial Orthop. 2011; 140 (1): 58-64.

  23. Sardarian A, Andisheh-Tadbir A, Zal F, Amini F, Jafarian A, Khademi F et al. Altered oxidative status and integrin expression in cyclosporine A-treated oral epithelial cells. Toxicol Mech Methods. 2015; 25 (2): 98-104.

  24. De Oliveira-Costa F, Diniz-Ferreira S, de Miranda-Cota LO, da Costa JE, Aguiar MA. Prevalence, severity, and risk variables associated with gingival overgrowth in renal transplant subjects treated under tacrolimus or cyclosporin regimens. J Periodontol. 2006; 77: 969-975.

  25. Radwan-Oczko M, Boratyńska M, Zietek M, Zołedziewska M, Jonkisz A. The relationship of transforming growth factor-beta1 gene polymorphism, its plasma level, and gingival overgrowth in renal transplant recipients receiving different immunosuppressive regimens. J Periodontol. 2006; 77 (5): 865-873.

  26. Banthia R, Gupta S, Banthia P, Singh P, Raje S, Kaur N. Is periodontal health a predictor of drug-induced gingival overgrowth? A cross-sectional study. Dent Res J (Isfahan). 2014; 11 (5): 579-584.

  27. Grover V, Kapoor A, Mayra CM. Amlodipine induced gingival hyperplasia. J Oral Health Comm Dent. 2007; 1 (1): 19-22.

  28. Seymour RA, Ellis JS, Thomason JM, Monkman S, Idle JR. Amlodipine-induced gingival overgrowth. J Clin Periodontol. 1994; 21: 281-283.

  29. Mironiuc-Cureu M, Dumitriu AS, Gheorghiu IM, Stoian IM. Gingival overgrowth as secondary effect of calcium channel blockers administration. A case report. J Med Life. 2014; 7 (2): 241-245.

  30. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol. 1996; 23 (3 Pt 1): 165-175.

  31. Alandia-Roman CC, Tirapelli C, Ribas P, Panzeri H. Drug-induced gingival overgrowth: a case report. Gen Dent. 2012; 60 (4): 312-315.

  32. Livada R, Shiloah J. Calcium channel blocker-induced gingival enlargement. J Hum Hypertens. 2014; 28 (1): 10-14.

  33. Heasman PA, Hughes FJ. Drugs, medications and periodontal disease. Br Dent J. 2014; 217 (8): 411-419.

  34. Pari A, Ilango P, Subbareddy V, Katamreddy V, Parthasarthy H. Gingival diseases in childhood - a review. J Clin Diagn Res. 2014; 8 (10): ZE01-4.

  35. Omori K, Hanayama Y, Naruishi K, Akiyama K, Maeda H, Otsuka F et al. Gingival overgrowth caused by vitamin C deficiency associated with metabolic syndrome and severe periodontal infection: a case report. Clin Case Rep. 2014; 2 (6): 286-295.

  36. Pego SP, Coletta RD, Mendes DC, de Faria PR, Melo-Filho MR, Alves LR et al. Hereditary gingival fibromatosis: clinical and ultrastructural features of a new family. Med Oral Patol Oral Cir Bucal. 2015; 20 (2): e150-e155.

  37. Kapoor A, Malhotra R, Grover V, Saxena D. Pregnancy associated gingival enlargement. J Oral Health Comm Dent. 2010; 4 (2): 48-51.

  38. Hassell TM, Page RC, Narayanan AS, Cooper CG. Diphenylhydantoin (dilantin) gingival hyperplasia: drug-induced abnormality of connective tissue. Proc Natl Acad Sci U S A. 1976; 73 (8): 2909-2912.

  39. Hassell TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Biol Med. 1991; 2 (1): 103-137.

  40. Dill RE, Miller EK, Weil T, Lesley S, Farmer GR, Iacopino AM. Phenytoin increases gene expression for platelet-derived growth factor B chain in macrophages and monocytes. J Periodontol. 1993; 64 (3): 169-173.

  41. Gong Y, Lu J, Ding X, Yu Y. Effect of adjunctive roxithromycin therapy on interleukin-1β, transforming growth factor-β1 and vascular endothelial growth factor in gingival crevicular fluid of cyclosporine A-treated patients with gingival overgrowth. J Periodontal Res. 2014; 49 (4): 448-457.

  42. Subramani T, Rathnavelu V, Alitheen NB. The possible potential therapeutic targets for drug induced gingival overgrowth. Mediators Inflamm. 2013; 2013: 639468.

  43. Trackman PC, Kantarci A. Molecular and clinical aspects of drug-induced gingival overgrowth. J Dent Res. 2015; 94 (4): 540-546.

  44. Lekkerkerker AN, Aarbiou J, van Es T, Janssen RA. Cellular players in lung fibrosis. Curr Pharm Des. 2012; 18 (27): 4093-4102.

  45. Carew RM, Wang B, Kantharidis P. The role of EMT in renal fibrosis. Cell Tissue Res. 2012; 347 (1): 103-116.




2020     |     www.medigraphic.com